Xias Bio’s engineered proteins: pioneering applications across multiple industries

The global reliance on animal-derived proteins in industries ranging from cosmetics to biotechnology presents significant ethical, environmental and sustainability challenges. Xias Bio set out to address this problem by creating a sustainable, multifunctional proteins that not only matches but exceeds the performance of animal-based alternatives using an innovative platform they call LiteProtein™.

Reimagining proteins for a better tomorrow

Xias Bio has developed a cutting-edge protein engineering platform, LiteProtein™, which allows for the creation of highly specialized, multifunctional proteins. This platform is built upon advanced biochemical and protein engineering techniques, enabling the production of chimeric proteins tailored to meet specific industrial needs. What sets LiteProtein™ apart is its flexibility and adaptability, allowing Xias Bio to quickly pivot and customize proteins for various applications, whether in cosmetics, personal care, biotechnology, or agriculture.

The LiteProtein™ platform operates by designing proteins that integrate multiple functional motifs into a single molecular framework, effectively replacing traditional animal-derived proteins while enhancing performance. These proteins are engineered for high yield and scalability, ensuring they can transition seamlessly from the lab to industrial-scale production.

David, Xias Bio’s co-founder, highlighted the unique capabilities of their platform: “Our LiteProtein™ platform is not just about replacing animal-derived proteins; it’s about creating something fundamentally better. We can develop proteins that deliver the same or enhanced functionality as animal-derived ingredients without the associated ethical and environmental drawbacks. This ability to engineer multifunctional proteins at an industrial scale opens up vast possibilities across various sectors.”

Collaborating for a sustainable future

Xias Bio’s partnership with Happiness Captial began during their participation in the SOSV IndieBio NY program. Recognizing the transformative potential of Xias Bio’s technology, Happiness Capital provided invaluable strategic support which has been instrumental in accelerating Xias Bio’s growth. Happiness Capital connected Xias Bio with a broad network of industry stakeholders, facilitating key partnerships and helping navigate complex regulatory environments. Their strategic guidance has enabled Xias Bio to sharpen its growth strategy, focusing on rapid market penetration and scaling.

Charting the future: Xias Bio’s next big moves

Since its inception, Xias Bio has made significant strides. The company has successfully developed and commercialized several families of multifunctional proteins, such as ElastiLite™ for fine line and wrinkle control in cosmetics, and CollaLite™, a collagen-based protein offering enhanced performance in various applications . These innovations have garnered interest from leading companies and positioned Xias Bio as a key player in the push towards more sustainable industrial practices.

Looking ahead, Xias Bio is poised for continued success. The company plans to expand its product offerings into new markets, including agriculture technology, where its proteins have shown promise in improving crop resilience and sustainability. Additionally, Xias Bio is exploring further applications of its technology in life sciences, with the potential to disrupt traditional manufacturing processes across multiple sectors.